Updates in version 4.2018 of the NCCN guidelines for non-small cell lung cancer from version 3.2018

NSCL-J 2 of 4

Adenocarcinoma, Large Cell, NSCLC NOS (PS 0–1)

Pembrolizumab/cisplatin/pemetrexed added as a firstline therapy option.

Cold weather and much snow in early winter, spring will come earlier next year; cold weather and much snow in midwinter, spring will come later next year.”

NSCL-J 4 of 4

Reference added: Gandhi L, Rodriguez-Abreu D,Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018[published online April 16, 2018].

公摊系数竟是“伪命题”。明源地产研究院执行主编艾振强说，事实上，作为国内房地产交易和收费重要依据的“公摊系数”这个术语，至今都没在现行国家标准中出现过。

Updates in version 3.2018 of the NCCN guidelines for non-small cell lung cancer from version 2.2018

DIAG-3

Solitary part-solid nodule(s); sub-categories modified:Persistent and ＜ 6 mm, delete “solid component”;Persistent and ≥ 6 mm, delete “solid component”.

Testing results clarification added: EGFR, ALK, ROS1,BRAF negative or unknown, PD-L1＜50% or unknown

Footnote ** added: Carboplatin-based regimens are often used for patients with comorbidities or those who cannot tolerate cisplatin.

Updates in Version 2.2018 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 1.2018 include:

NSCL-4 and NSCL-6

Added Stage IIIA (T4, N0-1)

NSCL-17

当α=1时，该广义熵指数就是泰尔指数。泰尔指数具有可加分解性，通过分解成为组内差异和组间差异，从而可以看出区域之间发展差距以及各区域内部发展差距。泰尔指数最终分解为：

NSCL-J 2 of 4 and 3 of 4

Sub-bullets added: If unchanged and solid component remains ＜ 6 mm, annual CT for 5 y; If solid component ≥6 mm, consider PET/CT or biopsy.

MS-1

The Discussion section has been updated to reflect the changes in the algorithm.